ESC Hot Line: STEP HFpEF: Once-Weekly Semaglutide in People with HFpEF and Obesity

Currently no approved therapies exist to target obesity-related heart failure with preserved ejection fraction, a condition increasing in prevalence and associated with high symptom burden. In this interview, Mikhail Kosiborod MD, and Alison L. Bailey MD, FACC, discuss ESC Hot Line: STEP HFpEF: once-weekly semaglutide in people with HFpEF and obesity. 

Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL